Merck & Co. Inc. (MRK) recently entered into agreements with Roche Holdings Ltd. (RHHBY) to bring about an improvement in the treatment, diagnosis and awareness of chronic hepatitis C (HCV) infection in developed and emerging markets.
Merck and Roche will also collaborate and study novel combinations of marketed and investigational drugs of both companies leading to an increase in the availability of potential new treatment regimens for patients suffering from HCV.
Per the terms of the non-exclusive agreements, Roche will promote Victrelis (boceprevir) in the US as a part of a triple combination therapy regimen. The companies plan to extend the agreement to other developed and emerging markets.
We note that the US Food and Drug Administration (FDA) approved Victrelis last week for the treatment of chronic hepatitis C infection. The drug is to be used in combination with peginterferon alfa and ribavirin, in treatment-na
Be the first to comment